혈액 관련 질환의 유병률 증가와 치료용 아페레시스 시술에 대한 수요 증가로 인해 아페레시스 시장은 괄목할 만한 성장세를 보이고 있습니다. 또한 아페레시스 장비와 일회용의 기술 발전은 치료 효과를 향상시켜 시장 확대에 기여하고 있습니다. 이에 따라 시장 규모는 2024년에 39억 9,000만 달러를 돌파하며, 2031년에는 약 63억 달러에 달할 전망입니다.
시장은 전 세계에서 확대되고 있으며, 북미가 주요 지역으로 부상하고 있습니다. 주요 촉진요인으로는 헬스케어 투자 증가와 치료용 아페레시스에 대한 인식 개선이 꼽힙니다. 아시아태평양의 신흥 시장도 환자 수 증가와 의료 인프라 개선에 힘입어 성장세를 보이고 있습니다. 아페레시스에 대한 수요가 증가함에 따라 시장은 2024-2031년 연평균 12.6%의 성장률을 보일 것으로 예상됩니다.
정의/개요
아페레시스는 혈장, 혈소판, 백혈구 등 특정 혈액 성분을 분리하여 제거한 후 남은 혈액을 환자에게 되돌려주는 의료 시술입니다.
아페레시스는 자가면역질환, 혈액질환, 심혈관질환 치료에 널리 사용되고 있습니다. 또한 혈장 및 혈소판 채취를 포함한 헌혈을 지원하여 다양한 임상 현장에서 환자 치료를 개선합니다.
아페레시스 시장은 기술 발전, 의료 인프라 확대, 특히 신흥 시장에서 혈액 성분 요법에 대한 수요 증가로 인해 향후 성장이 기대되는 시장입니다.
자가면역 질환, 혈액 악성 종양, 심혈관 질환과 같은 혈액 관련 질환의 빈도가 증가함에 따라 아페레시스 산업을 주도하고 있습니다. 이러한 질환은 특정 혈액 성분에 대한 치료가 자주 필요하므로 원하는 혈액 성분을 분리하고 회수하는 아페레시스 시술에 대한 수요가 증가하고 있습니다. 또한 아페레시스 기술의 혁신과 이러한 시술의 이점에 대한 의료 전문가들의 인식이 높아짐에 따라 시장 확대가 가속화되고 있습니다. 아페레시스 연구 및 개발에 대한 투자 증가는 치료 옵션을 넓히고 환자 결과를 개선할 수 있습니다. 또한 혈액 문제에 민감한 노인 인구 증가는 효과적인 아페레시스 치료에 대한 수요를 증가시켜 시장 성장을 가속하고 있습니다. 전반적으로 혈액 관련 질환의 유병률 증가는 아페레시스 시장의 중요한 촉진제입니다.
아페레시스 수술의 높은 비용은 시장 확대를 크게 제한하고 있습니다. 이러한 치료는 전문 장비, 전문 인력 및 병원의 막대한 자원을 필요로 하는 경우가 많으며, 그 결과 운영 비용이 증가합니다. 그 결과, 많은 의료 서비스 프로바이더가 아페레시스 기술에 대한 투자를 주저하고, 환자의 치료 접근성을 떨어뜨립니다. 또한 특히 보험 적용과 재정적 자원이 제한적인 지역에서는 높은 비용이 개인과 의료 시스템에 부담을 줄 수 있습니다. 이러한 높은 비용 장벽으로 인해 환자들이 아페레시스를 선택하지 않아 시장 수요를 감소시킬 수 있습니다. 또한 더 저렴한 대체 치료법과의 경쟁으로 인해 아페레시스 시장의 성장을 저해할 수 있습니다. 전반적으로, 높은 가격의 아페레시스 수술은 업계의 장기적인 성장에 큰 장벽이 될 것입니다.
The Apheresis Market is witnessing significant growth due to rising incidences of blood-related disorders and the increasing demand for therapeutic apheresis procedures. Technological advancements in apheresis devices and disposables are also contributing to the market's expansion, enhancing treatment efficacy. This is likely to enable the market size to surpass USD 3.99 Billion valued in 2024 to reach a valuation of around USD 6.3 Billion by 2031.
The market is expanding globally, with North America as the leading region. Key drivers include increasing healthcare investments and rising awareness of therapeutic apheresis. Emerging markets in Asia-Pacific are also gaining traction, driven by growing patient populations and improving healthcare infrastructure. The rising demand for apheresis is enabling the market to grow at aCAGR of 12.6% from 2024 to 2031.
Definition/Overview
Apheresis is a medical procedure used to separate and remove specific blood components, such as plasma, platelets, or white blood cells, while returning the remaining blood to the patient.
Apheresis is widely used in treating autoimmune disorders, hematological diseases and cardiovascular conditions. It also supports blood donations, including plasma and platelet collection, improving patient care in various clinical settings.
The apheresis market is poised for future growth, driven by advancements in technology, expanding healthcare infrastructure and increasing demand for blood component therapies, particularly in emerging markets.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The increasing frequency of blood-related ailments, such as autoimmune diseases, hematologic malignancies, and cardiovascular problems, is driving the apheresis industry. As these conditions frequently necessitate particular blood component therapy, the demand for apheresis procedures, which separate and collect targeted blood components, grows. Furthermore, innovations in apheresis technology and increasing awareness among healthcare professionals about the benefits of these procedures help to drive market expansion. Increasing investment in apheresis research and development expands treatment options and improves patient outcomes. Furthermore, the growing geriatric population, which is more sensitive to blood problems, increases the demand for effective apheresis treatments, driving market growth. Overall, the increasing prevalence of blood-related illnesses is a significant driver of the apheresis market.
The high cost of apheresis operations significantly limits the market's expansion. These treatments frequently necessitate specialized equipment, expert personnel, and substantial hospital resources, resulting in increasing operating expenses. As a result, many healthcare providers may hesitant to invest in apheresis technology, reducing patient access to these treatments. Furthermore, the high costs can put a strain on individuals and healthcare systems, particularly in areas with limited insurance coverage or financial resources. This expensive barrier may prevent patients from choosing for apheresis, reducing market demand. Furthermore, competition from less expensive alternative treatments may impede the apheresis market's growth. Overall, the high prices of apheresis operations represent a significant barrier to long-term industry growth.
The increasing adoption of automated technologies in apheresis devices is driving the growth of the segment by enhancing procedure accuracy, reducing manual errors and improving patient outcomes. These advanced devices offer greater efficiency in blood component separation, leading to their widespread use in both therapeutic and donation settings. As healthcare providers prioritize automation for better results and time savings, the demand for apheresis devices continues to grow, boosting the market segment's expansion.
The rising use of apheresis in treating autoimmune disorders is driving growth in the Application segment by providing effective, targeted therapies for conditions like multiple sclerosis and Guillain-Barre syndrome. Apheresis helps remove harmful antibodies or immune complexes, offering significant clinical benefits. As the prevalence of autoimmune diseases increases, the demand for apheresis treatments expands, leading to the growth of this segment in both therapeutic and healthcare applications.
North America's advanced healthcare infrastructure contributes significantly to the region's supremacy in the apheresis market. The well-established healthcare infrastructure make it easier to integrate innovative technologies, resulting in more efficient apheresis processes. Significant investments in cutting-edge medical technology improve the efficacy and accessibility of these therapies. Furthermore, growing awareness of the therapeutic benefits of apheresis, particularly for autoimmune diseases and hematologic disorders, is broadening the patient base. The region also benefits from a strong research climate, which promotes advances in apheresis technology. Additionally, regulatory backing and increasing healthcare expenditure help to drive market expansion. These factors combine to establish North America as a market leader in apheresis, fueling its sustained growth.
The growing healthcare investments and expanding patient population are key drivers of Asia-Pacific's rapid growth in the Apheresis Market. As countries like China and India enhance their healthcare infrastructure, demand for advanced therapeutic procedures increases. Additionally, the rising prevalence of blood-related disorders and increasing awareness of apheresis treatments fuel market expansion. This combination of factors is positioning Asia-Pacific as the fastest-growing region in the global apheresis market.
The apheresis market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.
Some of the prominent players operating in the Apheresis market include:
Asahi Kasei Corporation
Braun Melsungen AG
Cerus Corporation
Fresenius Kabi
Haemonetics Corporation
Charles River Laboratories International, Inc.
Kaneka Corporation
Kawasumi Laboratories Inc.
Nikkiso Co. Ltd
Terumo BCT
In September 2024, Fresenius Kabi announced the divestment of its IV manufacturing site in Chile to Medifarma, streamlining its production network as part of its Vision 2026 strategy.
In June 2024, Asahi Kasei Corporation introduced a new membrane system for the production of sterile water used in injections, enhancing its product offerings in the healthcare sector.
In August 2023, Terumo BCT, Inc. launched a training program initiative aimed at supporting cell and gene therapy manufacturers, which is expected to improve cell collection processes and boost therapeutic commercialization.
In March 2024, Haemonetics Corporation received FDA approval for its new apheresis device designed to enhance the efficiency of blood component collection, marking a significant advancement in their product line.